173 related articles for article (PubMed ID: 32782542)
1. Stanniocalcin 1 is a prognostic biomarker in glioma.
Luo W; Chen D; Wang H; Hu J
Oncol Lett; 2020 Sep; 20(3):2248-2256. PubMed ID: 32782542
[TBL] [Abstract][Full Text] [Related]
2. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
3. Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients.
Su J; Guo B; Zhang T; Wang K; Li X; Liang G
Tumour Biol; 2015 Aug; 36(8):6333-9. PubMed ID: 25783529
[TBL] [Abstract][Full Text] [Related]
4. Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas.
Wang H; Zhao Y; Zhang C; Li M; Jiang C; Li Y
PLoS One; 2014; 9(2):e89782. PubMed ID: 24587032
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
6. ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2
Zhang Y; Wang K; Zhao Z; Sun S; Zhang K; Huang R; Zeng F; Hu H
Cancer Cell Int; 2018; 18():196. PubMed ID: 30524204
[TBL] [Abstract][Full Text] [Related]
7. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
9. Expression and Prognostic Role of PLOD1 in Malignant Glioma.
Wang H; Luo W; Dai L
Onco Targets Ther; 2020; 13():13285-13297. PubMed ID: 33402837
[TBL] [Abstract][Full Text] [Related]
10. Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma.
Liu J; Gao L; Liao J; Yang J; Yuan F; Chen Q
Ann Transl Med; 2021 Feb; 9(3):260. PubMed ID: 33708887
[TBL] [Abstract][Full Text] [Related]
11. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
14. An immune-related lncRNA signature for patients with anaplastic gliomas.
Wang W; Zhao Z; Yang F; Wang H; Wu F; Liang T; Yan X; Li J; Lan Q; Wang J; Zhao J
J Neurooncol; 2018 Jan; 136(2):263-271. PubMed ID: 29170907
[TBL] [Abstract][Full Text] [Related]
15. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
Chen Y; Guo Y; Chen H; Ma F
Front Neurol; 2020; 11():573264. PubMed ID: 33329315
[No Abstract] [Full Text] [Related]
16. Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.
Zhao S; Cai J; Li J; Bao G; Li D; Li Y; Zhai X; Jiang C; Fan L
Mol Neurobiol; 2017 Dec; 54(10):8203-8210. PubMed ID: 27900679
[TBL] [Abstract][Full Text] [Related]
17. CDH2 expression is of prognostic significance in glioma and predicts the efficacy of temozolomide therapy in patients with glioblastoma.
Chen Q; Cai J; Jiang C
Oncol Lett; 2018 May; 15(5):7415-7422. PubMed ID: 29731893
[TBL] [Abstract][Full Text] [Related]
18. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
19. Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of
Wang H; Wang X; Xu L; Zhang J; Cao H
Front Oncol; 2021; 11():551160. PubMed ID: 33959491
[No Abstract] [Full Text] [Related]
20. RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
Zeng F; Wang K; Huang R; Liu Y; Zhang Y; Hu H
Oncol Lett; 2019 Jul; 18(1):386-394. PubMed ID: 31289510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
